KR101557832B1 - (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 - Google Patents

(ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 Download PDF

Info

Publication number
KR101557832B1
KR101557832B1 KR1020107013939A KR20107013939A KR101557832B1 KR 101557832 B1 KR101557832 B1 KR 101557832B1 KR 1020107013939 A KR1020107013939 A KR 1020107013939A KR 20107013939 A KR20107013939 A KR 20107013939A KR 101557832 B1 KR101557832 B1 KR 101557832B1
Authority
KR
South Korea
Prior art keywords
compound
acid
salt
tartrate
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107013939A
Other languages
English (en)
Korean (ko)
Other versions
KR20100103532A (ko
Inventor
후안 로렌조 카테나 루이즈
호세 히달고 로드리구에즈
마리아 델 카르멘 세라 코마스
이사벨 마십 마십
Original Assignee
라보라토리오스 살바트, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라보라토리오스 살바트, 에스.에이. filed Critical 라보라토리오스 살바트, 에스.에이.
Publication of KR20100103532A publication Critical patent/KR20100103532A/ko
Application granted granted Critical
Publication of KR101557832B1 publication Critical patent/KR101557832B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020107013939A 2007-11-28 2008-11-28 (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염 Expired - Fee Related KR101557832B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07384038.1 2007-11-28
EP07384038A EP2065385A1 (en) 2007-11-28 2007-11-28 Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester

Publications (2)

Publication Number Publication Date
KR20100103532A KR20100103532A (ko) 2010-09-27
KR101557832B1 true KR101557832B1 (ko) 2015-10-06

Family

ID=39401152

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107013939A Expired - Fee Related KR101557832B1 (ko) 2007-11-28 2008-11-28 (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염

Country Status (18)

Country Link
US (2) US8492402B2 (https=)
EP (2) EP2065385A1 (https=)
JP (1) JP5336509B2 (https=)
KR (1) KR101557832B1 (https=)
CN (1) CN101925600B (https=)
AU (1) AU2008329181B2 (https=)
BR (1) BRPI0819607A2 (https=)
CA (1) CA2706565C (https=)
DK (1) DK2220082T3 (https=)
EA (1) EA017483B1 (https=)
ES (1) ES2498819T3 (https=)
IL (1) IL206032A (https=)
MX (1) MX2010005850A (https=)
NZ (1) NZ585833A (https=)
PL (1) PL2220082T3 (https=)
UA (1) UA102083C2 (https=)
WO (1) WO2009068253A2 (https=)
ZA (1) ZA201003718B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
EP2534153B2 (en) 2010-02-12 2024-05-22 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
KR101978364B1 (ko) * 2017-06-15 2019-05-14 크리스탈지노믹스(주) 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 또는 그 유도체의 약학적으로 허용 가능한 염 및 그 제조방법
KR102678356B1 (ko) * 2018-10-29 2024-06-26 씨지인바이츠 주식회사 알킬카바모일 나프탈렌일옥시 옥테노일 하이드록시아마이드 인산염, 타르타르산염 또는 이들의 조합을 포함하는 약제학적 조성물 및 그 제조방법
US12553903B2 (en) 2023-06-01 2026-02-17 Cg Pharmaceuticals, Inc Ivaltinostat combination therapy for treating pancreatic cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063950A1 (en) * 2000-06-27 2004-04-01 Carles Farrerons Gallemi Carbamates derivatived from arylakylamines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
EP1461336B1 (en) 2001-12-20 2013-05-22 CHIESI FARMACEUTICI S.p.A. 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2246170B1 (es) * 2004-07-29 2007-04-01 Almirall Prodesfarma, S.A. Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063950A1 (en) * 2000-06-27 2004-04-01 Carles Farrerons Gallemi Carbamates derivatived from arylakylamines

Also Published As

Publication number Publication date
EP2220082A2 (en) 2010-08-25
EP2220082B1 (en) 2014-06-25
EA017483B1 (ru) 2012-12-28
JP5336509B2 (ja) 2013-11-06
MX2010005850A (es) 2010-09-03
CN101925600A (zh) 2010-12-22
WO2009068253A3 (en) 2009-08-13
CA2706565C (en) 2015-04-28
JP2011504890A (ja) 2011-02-17
BRPI0819607A2 (pt) 2015-10-13
HK1144192A1 (en) 2011-02-02
WO2009068253A2 (en) 2009-06-04
EP2065385A1 (en) 2009-06-03
NZ585833A (en) 2011-05-27
US20110207769A1 (en) 2011-08-25
KR20100103532A (ko) 2010-09-27
US8492402B2 (en) 2013-07-23
ES2498819T3 (es) 2014-09-25
US20140051721A1 (en) 2014-02-20
DK2220082T3 (da) 2014-10-06
CN101925600B (zh) 2013-01-09
US8871787B2 (en) 2014-10-28
CA2706565A1 (en) 2009-06-04
EA201070651A1 (ru) 2010-12-30
IL206032A (en) 2014-07-31
AU2008329181A1 (en) 2009-06-04
IL206032A0 (en) 2010-11-30
UA102083C2 (uk) 2013-06-10
ZA201003718B (en) 2011-08-31
AU2008329181B2 (en) 2012-03-29
PL2220082T3 (pl) 2014-12-31

Similar Documents

Publication Publication Date Title
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
CN102448963B (zh) 7-[(3R,4R)-3-羟基-4-羟基甲基-吡咯烷-1-基甲基]-3,5-二氢-吡咯并[3,2-d]嘧啶-4-酮的有用药学上的盐
JP5086069B2 (ja) 重硫酸アタザナビルおよび新規形態の製造方法
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
KR101557832B1 (ko) (ｒ)-3-플루오로페닐-3,4,5-트리플루오로벤질카르밤산 1-아자비시클로 [2.2.2]옥트-3-일 에스테르의 안정한 결정성 염
US20100016593A1 (en) Crystalline forms of palonosetron hydrochloride
US20030191347A1 (en) Venlafaxine base
CN101959846A (zh) 新的o-去甲基-文拉法辛盐
TWI445697B (zh) 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式
JP2025508792A (ja) ジペプチジルペプチダーゼ阻害化合物の塩及び結晶形態
CN101098850B (zh) 西布曲明的无机酸盐
CN117377658A (zh) 喹啉衍生物化合物的制备方法
CN1980666B (zh) 制备阿扎那韦硫酸氢盐的方法和新的形式
CN1880294B (zh) 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物
KR100536750B1 (ko) 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물
HK1144192B (en) Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
KR20060103997A (ko) 신규한 결정형 시부트라민 유기산염과 그의 제조방법
TW202540105A (zh) 1-((3S,4R)-3-((2-((1-乙基-1H-吡唑-4-基)胺基)-7H-吡咯并[2,3-d]嘧啶-4-基)氧基)-4-氟哌啶-1-基)丙-2-烯-1-酮之酒石酸鹽、其結晶形式及其製備方法
KR20110095545A (ko) (ｓ)-리바스티그민 오로트산염 및 이를 포함하는 약제학적 조성물
US20050215600A1 (en) Polymorphs of torsemide hydrochloride and process for production thereof
US20180362444A1 (en) Process for the preparation of enclomiphene citrate having needle shaped crystal habit
EP3210975A1 (en) Cocrystals of lorcaserin
CZ426199A3 (cs) Nová sůl
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt
JPWO1999002522A1 (ja) （ｒ）−ｎ−（１−エチル−１ｈ−ヘキサヒドロアゼピン−３−イル）−６−メトキシ−１ｈ−ベンゾトリアゾール−５−カルボキサミド１フマル酸塩１水和物及びその製造方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20181001

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20181001